Latest & greatest articles for calcium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on calcium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on calcium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for calcium

321. A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty

A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty Hillegass W B, Ohman E M, Leimberger J D, Califf R M Authors' objectives The study assesses the usefulness of calcium antagonists in reducing restenosis after (...) coronary angioplasty. Searching MEDLINE was searched from 1980 to 1993, as were abstracts from the American College of Cardiology, American Heart Association, and the European Congress of Cardiology. Reference lists of all identified studies were also examined. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included. Specific interventions included in the review Calcium antagonists. Participants included in the review Patients who have undergone

DARE.1994

322. Calcium antagonists in the treatment of ischemic heart disease: myocardial infarction

Calcium antagonists in the treatment of ischemic heart disease: myocardial infarction Calcium antagonists in the treatment of ischemic heart disease: myocardial infarction Calcium antagonists in the treatment of ischemic heart disease: myocardial infarction Held P H, Yusuf S Authors' objectives To assess the benefit of calcium antagonists during and after acute myocardial infarction (MI). Searching The authors do not state which sources were searched, or how the search was performed; further (...) , but it appears that a cautious approach should be taken to using a calcium antagonist in patients with signs and symptoms of left ventricular dysfunction. CRD commentary It is not possible to judge whether the review is comprehensive and unbiased since the authors do not state their search strategy or the methods that they use in reviewing the studies. The results of the two subgroup analyses should be treated with great caution as presentation of these subgroups in the literature is likely

DARE.1994

323. Effect of calcium supplementation on bone loss in postmenopausal women.

Effect of calcium supplementation on bone loss in postmenopausal women. 8421475 1993 02 18 1993 02 18 2013 11 21 0028-4793 328 7 1993 Feb 18 The New England journal of medicine N. Engl. J. Med. Effect of calcium supplementation on bone loss in postmenopausal women. 460-4 The use of calcium supplements slows bone loss in the forearm and has a beneficial effect on the axial bone density of women in late menopause whose calcium intake is less than 400 mg per day. However, the effect of a calcium (...) supplement of 1000 mg per day on the axial bone density of postmenopausal women with higher calcium intakes is not known. We studied 122 normal women at least three years after they had reached menopause who had a mean dietary calcium intake of 750 mg per day. The women were randomly assigned to treatment with either calcium (1000 mg per day) or placebo for two years. The bone mineral density of the total body, lumbar spine, and proximal femur was measured every six months by dual-energy x-ray

NEJM1993

324. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.

Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. 7684512 1993 06 22 1993 06 22 2013 11 21 0028-4793 328 24 1993 Jun 17 The New England journal of medicine N. Engl. J. Med. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. 1747-52 Prolonged corticosteroid therapy increases the risk of osteoporosis and fracture. We studied whether corticosteroid-induced osteoporosis could be prevented by treatment (...) with calcium, calcitriol (1,25-dihydroxyvitamin D3), and calcitonin. One hundred three patients starting long-term corticosteroid therapy were randomly assigned to receive 1000 mg of calcium per day orally and either calcitriol (0.5 to 1.0 microgram per day orally) plus salmon calcitonin (400 IU per day intranasally), calcitriol plus a placebo nasal spray, or double placebo for one year. Data on treatment efficacy were available for 92 of these patients. Bone density was measured every four months for two

NEJM1993

325. Calcium supplementation and bone mineral density in adolescent girls.

Calcium supplementation and bone mineral density in adolescent girls. 8340983 1993 08 31 1993 08 31 2016 10 17 0098-7484 270 7 1993 Aug 18 JAMA JAMA Calcium supplementation and bone mineral density in adolescent girls. 841-4 To evaluate the effect of calcium supplementation on bone acquisition in adolescent white girls. A randomized, double-blind, placebo-controlled trial of the effect of 18 months of calcium supplementation on bone density and bone mass. Ninety-four girls with a mean age (...) of 11.9 + 0.5 years at study entry. University hospital in a small town. Calcium supplementation, 500 mg/d calcium as calcium citrate malate; controls received placebo pills. Bone mineral density and bone mineral content of the lumbar spine and total body were measured by dual-energy x-ray absorptiometry and calcium excretion from 24-hour urine specimens. Calcium intake from dietary sources averaged 960 mg/d for the entire study group. The supplemented group received, on average, an additional 354 mg

JAMA1993

326. Treatment of postmenopausal osteoporosis with calcitriol or calcium.

Treatment of postmenopausal osteoporosis with calcitriol or calcium. 1729617 1992 02 11 1992 02 11 2013 11 21 0028-4793 326 6 1992 Feb 06 The New England journal of medicine N. Engl. J. Med. Treatment of postmenopausal osteoporosis with calcitriol or calcium. 357-62 Osteoporosis is a common problem whose management is controversial. To evaluate the efficacy and safety of calcitriol (1,25-dihydroxyvitamin D3) in the treatment of postmenopausal osteoporosis, we conducted a three-year prospective (...) , multicenter, single-blind study in 622 women who had one or more vertebral compression fractures. The women were randomly assigned to receive treatment with calcitriol (0.25 micrograms twice a day) or supplemental calcium (1 g of elemental calcium daily) for three years. New vertebral fractures were detected by means of lateral roentgenography of the spine each year, and calcium absorption was measured in 392 of the women. The women who received calcitriol had a significant reduction in the rate of new

NEJM1992

327. Calcium supplementation to prevent hypertensive disorders of pregnancy.

Calcium supplementation to prevent hypertensive disorders of pregnancy. 1922250 1991 11 20 1991 11 20 2013 11 21 0028-4793 325 20 1991 Nov 14 The New England journal of medicine N. Engl. J. Med. Calcium supplementation to prevent hypertensive disorders of pregnancy. 1399-405 Calcium supplementation has been reported to reduce blood pressure in pregnant and nonpregnant women. We undertook this prospective study to determine the effect of calcium supplementation on the incidence of hypertensive (...) disorders of pregnancy (gestational hypertension and preeclampsia) and to determine the value of urinary calcium levels as a predictor of the response. We studied 1194 nulliparous women who were in the 20th week of gestation at the beginning of the study. The women were randomly assigned to receive 2 g per day of elemental calcium in the form of calcium carbonate (593 women) or placebo (601 women). Urinary excretion of calcium and creatinine was measured before calcium supplementation was begun

NEJM1991

328. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy.

Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. 1922205 1991 10 29 1991 10 29 2013 11 21 0028-4793 325 17 1991 Oct 24 The New England journal of medicine N. Engl. J. Med. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. 1189-95 Osteoporosis among older women is a major public health problem. We studied the effects of three (...) approaches to the prevention of osteoporosis in women with low bone density. One hundred twenty postmenopausal women (mean [+/- SD] age, 56 +/- 4) who were selected because they had low forearm bone density were enrolled in a double-blind, placebo-controlled, randomized study comparing the effects of an exercise regimen (exercise group, n = 41), exercise plus dietary calcium supplementation (exercise-calcium group, n = 39), and exercise plus continuous replacement of estrogen and progesterone (exercise

NEJM1991

329. A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest. Brain Resuscitation Clinical Trial II Study Group.

A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest. Brain Resuscitation Clinical Trial II Study Group. 2014035 1991 05 15 1991 05 15 2013 11 21 0028-4793 324 18 1991 May 02 The New England journal of medicine N. Engl. J. Med. A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest. Brain Resuscitation Clinical Trial II Study Group. 1225-31 (...) Abnormalities of cellular calcium homeostasis have been implicated in the pathophysiology of postischemic encephalopathy. Calcium-entry-blocking drugs inhibit the influx of calcium into cells and have been shown to mitigate postischemic encephalopathy in animal models. Five hundred twenty patients with cardiac arrest who remained comatose after the restoration of spontaneous circulation were randomly assigned to receive three doses of lidoflazine, an experimental calcium-entry blocker, or a placebo and were

NEJM1991

330. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women.

A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. 2203964 1990 10 10 1990 10 10 2013 11 21 0028-4793 323 13 1990 Sep 27 The New England journal of medicine N. Engl. J. Med. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. 878-83 Background. The effectiveness of calcium in retarding bone loss in older postmenopausal women is unclear. Earlier work suggested that the women who were most likely (...) to benefit from calcium supplementation were those with low calcium intakes. Methods. We undertook a double-blind, placebo-controlled, randomized trial to determine the effect of calcium on bone loss from the spine, femoral neck, and radius in 301 healthy postmenopausal women, half of whom had a calcium intake lower than 400 mg per day and half an intake of 400 to 650 mg per day. The women received placebo or either calcium carbonate or calcium citrate malate (500 mg of calcium per day) for two years

NEJM1990

331. Effect of the time of administration of calcium acetate on phosphorus binding.

Effect of the time of administration of calcium acetate on phosphorus binding. 2710173 1989 05 26 1989 05 26 2013 11 21 0028-4793 320 17 1989 Apr 27 The New England journal of medicine N. Engl. J. Med. Effect of the time of administration of calcium acetate on phosphorus binding. 1110-3 Phosphorus binders are given to patients with renal failure to increase gastrointestinal excretion of phosphorus. To determine the relative importance of the binding of dietary as compared with endogenous (...) phosphorus and to determine the optimal dose schedule, we gave either 4.4 g of calcium acetate (25 mmol of calcium) or a placebo to six normal subjects on each of seven different schedules in a randomized sequence. The net gastrointestinal balance of phosphorus and calcium was determined by a one-day lavage technique. After a meal containing approximately 12 mmol of phosphorus, the mean phosphorus absorption (+/- SE) measured 9.17 +/- 0.36 mmol (78 percent) with placebo but decreased to 3.81 +/- 0.58

NEJM1989

332. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. The SCATI (Studio sulla Calciparina nell'Angina e nella Trombosi Ventricolare nell'Infarto) Group.

Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. The SCATI (Studio sulla Calciparina nell'Angina e nella Trombosi Ventricolare nell'Infarto) Group. 2568520 1989 08 23 1989 08 23 2015 06 16 0140-6736 2 8656 1989 Jul 22 Lancet (London, England) Lancet Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. The SCATI (Studio sulla Calciparina nell'Angina e nella Trombosi Ventricolare nell'Infarto) Group. 182-6 (...) In a multicentre study 711 patients were randomised to a group receiving calcium-heparin, 12,500 U, subcutaneously (360), or to a group receiving no heparin (351), beginning within 24 h of the onset of symptoms. 433 of these patients, admitted within 6 h, were given intravenous streptokinase (SK). Results were analysed for the in-hospital period. Calcium-heparin had no significant effects on the frequency of electrocardiographically documented ischaemic episodes or non-fatal reinfarction in the whole series

Lancet1989

333. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview.

Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. 2513047 1990 02 07 1990 02 07 2013 10 02 0959-8138 299 6709 1989 Nov 11 BMJ (Clinical research ed.) BMJ Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. 1187-92 To assess the effects of calcium channel blockers on development of infarcts, reinfarction, and mortality. A systematic overview of all randomised trials of calcium channel blockers in myocardial infarction (...) treatment was started some weeks later and continued for a year or two. There was no evidence of heterogeneity among different calcium channel blockers in their effects on any end point. The results were similar in the unstable angina trials (110 out of 561 patients treated with calcium channel blocker compared with 104 out of 548 controls developed a myocardial infarction; 14 out of 591 treated compared with nine out of 578 controls died). Calcium channel blockers do not reduce the risk of initial

BMJ1989 Full Text: Link to full Text with Trip Pro

334. Dietary intake of calcium and postmenopausal bone loss.

Dietary intake of calcium and postmenopausal bone loss. 3261612 1988 09 27 1988 09 27 2013 11 21 0959-8138 297 6640 1988 Jul 02 BMJ (Clinical research ed.) BMJ Dietary intake of calcium and postmenopausal bone loss. 15-7 The use of calcium supplements to prevent postmenopausal bone loss and hence osteoporosis is widespread, but the evidence for their efficacy, either alone or in combination with other treatments, is contradictory. Skeletal measurements and dietary intake of calcium were (...) determined in 59 healthy postmenopausal women, most of whom were within five years of the menopause. No correlation was found between current intake of calcium and either total calcium in the body or the density of trabecular or cortical bone in the forearm or vertebral trabecular bone. Dietary intake of calcium did not influence the rate of postmenopausal bone loss in the 54 women who completed 12 months of active or placebo treatment. Even when extremes of calcium intake were examined no difference

BMJ1988 Full Text: Link to full Text with Trip Pro

335. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study.

Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. 3540668 1987 02 11 1987 02 11 2013 11 21 0028-4793 316 4 1987 Jan 22 The New England journal of medicine N. Engl. J. Med. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. 173-7 During a two-year study, we examined the effect of calcium supplementation on postmenopausal bone loss in 43 women in the early postmenopausal period who were (...) assigned to one of three treatment groups: percutaneous 17 beta-estradiol (combined with progesterone during the second year), oral calcium (2000 mg daily), and placebo. All participants were examined every three months. Bone mineral content in the forearm (measured by single-photon absorptiometry) and in the entire body and spine (measured by dual-photon absorptiometry) remained constant in the estrogen-treated group but decreased significantly in the groups receiving calcium and placebo

NEJM1987

336. Blood pressure and metabolic effects of calcium supplementation in normotensive white and black men.

Blood pressure and metabolic effects of calcium supplementation in normotensive white and black men. 3820493 1987 04 16 1987 04 16 2016 10 17 0098-7484 257 13 1987 Apr 03 JAMA JAMA Blood pressure and metabolic effects of calcium supplementation in normotensive white and black men. 1772-6 A randomized, double-blind, placebo-controlled trial was conducted to examine the effect of calcium supplementation on blood pressure in normotensive black (n = 21) and white (n = 54) men, aged 19 to 52 years (...) . After a four-week baseline period of weekly blood pressure measurement, subjects were randomly assigned within racial groups to either a treatment (calcium, 1500 mg/d) or placebo group for a 12-week period. During the experimental period, multiple blood pressure measurements were taken every two weeks in both the seated and supine positions, using a random baseline sphygmomanometer. A repeated-measures analysis of covariance yielded a modest but significantly lower seated mean arterial pressure

JAMA1987

337. Gastrointestinal absorption of calcium from milk and calcium salts.

Gastrointestinal absorption of calcium from milk and calcium salts. 3614304 1987 09 17 1987 09 17 2013 11 21 0028-4793 317 9 1987 Aug 27 The New England journal of medicine N. Engl. J. Med. Gastrointestinal absorption of calcium from milk and calcium salts. 532-6 Whether ingested calcium is absorbed more efficiently from freely water-soluble calcium salts than from poorly soluble salts is unclear. It is also unknown whether calcium is absorbed better from dairy products than from calcium salts (...) . Using a method by which the net absorption of calcium can be accurately measured after a single dose, we studied eight healthy fasting subjects after they took a 500-mg dose of calcium from each of five calcium salts with various degrees of water solubility and from milk. The order of administration of the agents given was randomly determined. The mean (+/- SEM) net calcium absorption, in decreasing order of the solubility of the salts, was 32 +/- 4 percent from calcium acetate, 32 +/- 4 percent

NEJM1987

338. Effect of calcium supplementation on diastolic blood pressure in young people with mild hypertension.

Effect of calcium supplementation on diastolic blood pressure in young people with mild hypertension. 2876183 1986 10 30 1986 10 30 2015 06 16 0140-6736 2 8509 1986 Sep 27 Lancet (London, England) Lancet Effect of calcium supplementation on diastolic blood pressure in young people with mild hypertension. 703-7 In a double-blind trial 90 mildly hypertensive subjects aged 16-29 years were randomly assigned to 1 g calcium per day or placebo. Calcium supplementation did not affect systolic blood (...) pressure, but at six and twelve weeks diastolic blood pressure had fallen by 3.1 (p = 0.04) and 2.4 (p = 0.11) mm Hg, respectively, more in the calcium group than it had in the placebo group. Subjects with a baseline plasma parathyroid hormone (PTH) higher than the median showed a 6.1 mm Hg (p = 0.01) greater fall in diastolic blood pressure after six weeks and 5.4 mm Hg (p = 0.01) after twelve than in the placebo group. The fall in diastolic blood pressure was greater in the calcium group than in the placebo

Lancet1986

339. Randomized trial of allopurinol in the prevention of calcium oxalate calculi.

Randomized trial of allopurinol in the prevention of calcium oxalate calculi. 3534570 1986 12 15 1986 12 15 2013 11 21 0028-4793 315 22 1986 Nov 27 The New England journal of medicine N. Engl. J. Med. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. 1386-9 In a double-blind study, we examined the efficacy of allopurinol in the prevention of recurrent calcium oxalate calculi of the kidney. Sixty patients with hyperuricosuria and normocalciuria who had a history (...) was found to have a significantly longer time before recurrence of calculi (P less than 0.02). We conclude that allopurinol is effective in the prevention of calcium oxalate stones in patients with hyperuricosuria. The large reduction in the frequency of calculi in the placebo group underscores the positive treatment bias that regularly occurs in trials of prophylaxis against renal calculi when historical controls are used. Ettinger B B Tang A A Citron J T JT Livermore B B Williams T T eng Clinical

NEJM1986

340. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics.

Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. 2859465 1985 06 06 1985 06 06 2015 06 16 0140-6736 1 8436 1985 May 04 Lancet (London, England) Lancet Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. 1014-6 After they had been weaned off alcohol in hospital 85 severe alcoholics (above 200 g alcohol/day) were included in a double-blind study of calcium bis acetyl homotaurine (Ca AOTA, 25 mg/kg

Lancet1985